2017
DOI: 10.1038/ncomms15327
|View full text |Cite
|
Sign up to set email alerts
|

Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy

Abstract: Viral infections lead to alarmin release and elicit potent cytotoxic effector T lymphocyte (CTLeff) responses. Conversely, the induction of protective tumour-specific CTLeff and their recruitment into the tumour remain challenging tasks. Here we show that lymphocytic choriomeningitis virus (LCMV) can be engineered to serve as a replication competent, stably-attenuated immunotherapy vector (artLCMV). artLCMV delivers tumour-associated antigens to dendritic cells for efficient CTL priming. Unlike replication-def… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

10
126
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

4
5

Authors

Journals

citations
Cited by 71 publications
(136 citation statements)
references
References 69 publications
10
126
0
Order By: Relevance
“…IL-33 could also indirectly activate effector T cells. For instance, a replicating viral vector system used in cancer immunotherapy which delivers tumor-associated antigens to DC for efficient cytotoxic T cells priming, depends on IL-33 signaling ( 129 ). IL-33 could likewise increase T cell activation to promote graft- vs.-leukemia (GVL) reactions while decreasing fatal graft-vs.-host- disease (GVHD) ( 130 ).…”
Section: Discussionmentioning
confidence: 99%
“…IL-33 could also indirectly activate effector T cells. For instance, a replicating viral vector system used in cancer immunotherapy which delivers tumor-associated antigens to DC for efficient cytotoxic T cells priming, depends on IL-33 signaling ( 129 ). IL-33 could likewise increase T cell activation to promote graft- vs.-leukemia (GVL) reactions while decreasing fatal graft-vs.-host- disease (GVHD) ( 130 ).…”
Section: Discussionmentioning
confidence: 99%
“…Recombinant LCMV strains were generated according to established methods (Kallert et al, 2017;Kreutzfeldt et al, 2013). The following virus strains were used: recombinant LCMV encoding for the glycoprotein of vesicular stomatitis virus (VSV) instead of its own glycoprotein (rLCMV/ INDG, abbreviated rLCMV throughout); rLCMV encoding for Cre recombinase (rLCMV-Cre); LCMVwt (Armstrong strain).…”
Section: Virus Infectionmentioning
confidence: 99%
“…S1A ). Systemic infection with lymphocytic choriomeningitis virus (LCMV)-OVA, a replication-competent, attenuated LCMV mutant expressing ovalbumin (OVA) as model antigen ( 33 ), led to transient and low viral titers in spleen on day 3 p.i. that remained below the detection limit in PLN and SMG ( Fig.…”
Section: Resultsmentioning
confidence: 99%
“…transferred into recipient mice 24 h before i.p. infection with 10 5 pfu LCMV-OVA ( 33 ). Experimental read-outs for the acute, cleared and memory phase of viral infection were performed 6, 15 and ≥ 30 days p.i., respectively.…”
Section: Methodsmentioning
confidence: 99%